Samsara Vision Welcomes Julia M. Williams as New VP, WW Clinical and Medical Affairs
Far Hills, NJ – (July 28, 2021) – Samsara Vision, a company focused on bringing vision and freedom back to late-stage, age-related macular degeneration (AMD) patients through advanced visual prosthetic devices, today announces that Julia M. Williams will join the executive leadership team as Vice President, WW Clinical and Medical Affairs.
“At Samsara Vision, our growth is fueled by a team whose passion, creativity, and professionalism drives every step we take to bring our novel implantable devices to a larger population of adults whose vision is significantly impacted by macular degeneration. We are excited to welcome Julia to our organization as her comprehensive ophthalmology experience will immediately impact how we advance our research and our patient community’s access to technology,” said Thomas Ruggia, Chief Executive Officer, Samsara Vision.
Julia M. Williams joins Samsara Vision with over 25 years of ophthalmic experience encompassing the therapeutic areas of retina, glaucoma, dry eye, and cornea/external disease. Ms. Williams was most recently Vice President, Global Medical Affairs at Aerie Pharmaceuticals and she has held roles at Allergan, Heidelberg Engineering, and Bausch & Lomb. Ms. Williams also worked for five years as a Research Supervisor at Shiley Eye Institute at the University of California San Diego, which is where she earned her Bachelor of Science in Cognitive Neuroscience, Master’s degree in Visual Psychophysics and a micro MBA from the Rady School of Management. Across her roles, she has built and effectively led multidisciplinary teams specific to ophthalmology across marketing, clinical and medical affairs functions in support of over 15 successful product launches.
“I’ve devoted my career to helping preserve and improve vision for the patient community. I’m excited to join the Samsara Vision team at a time when we’re poised to expand our research and clinical activities,” said Ms. Williams, Vice President, WW Clinical and Medical Affairs.
About Late-Stage AMD
More than 15 million Americans are affected by some form of macular degeneration and approximately 2 million Americans have advanced forms of AMD with associated vision loss. The number of Americans afflicted with macular degeneration is expected to double with the rapid aging of the U.S. population. Late-stage AMD results in a loss of central or “straight-ahead” vision, creating a blind spot that is uncorrectable by glasses, drugs, injections or cataract surgery. This blind spot makes it difficult or impossible for patients to see faces, read, and perform everyday activities such as watching TV, preparing meals, and self-care. End-Stage AMD is the leading cause of blindness in older Americans.
About Samsara Vision
Samsara Vision is a privately held specialty medical device company engaged in the research, development, manufacture, and marketing of proprietary implantable ophthalmic devices and technologies that are intended to significantly improve vision and quality of life for individuals with untreatable retinal disorders. We believe that rejuvenating eyesight revives the spirit, allowing people to reconnect to the things in life that they love to see and do. Our approach includes working collaboratively with health care providers, researchers, payers, and advocates to ensure that people living with deteriorating vision have access to our novel technologies and support paths thereby better ensuring a future where they can see anew. Learn more at https://www.samsaravision.com/
Safe Harbor Statement
This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. Forward-looking statements include those about the belief that the company’s name change better reflects Samsara’s patient centricity and focus and the belief that rejuvenating eyesight revives the spirit, allowing people to reconnect to the things in life that they love to see and do. These forward-looking statements and their implications are based on the current expectations of the management of Samsara only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: claims by other companies and persons regarding ownership over intellectual property; changes in technology and market requirements; Samsara may encounter delays or obstacles in launching and/or successfully completing its clinical trials; Samsara’s products may not be approved by regulatory agencies, Samsara’s technology may not be validated as it progresses further and its methods may not be accepted by the scientific community; Samsara may be unable to retain or attract key employees whose knowledge is essential to the development of its products; unforeseen scientific difficulties may develop with Samsara’s process; Samsara’s products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; Samsara’s patents may not be sufficient; Samsara’s products may harm recipients; changes in legislation may adversely impact Samsara; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Samsara to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Samsara undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Released July 28, 2021